InsiderTrades.com logo
[Urgent] Starlink Set For The Largest IPO In History?
From Paradigm Press   |   Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
Click here now for the urgent details on this hidden play.
Nello Mainolfi net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Nello Mainolfi Biography and Net Worth

CEO of Kymera Therapeutics
Nello started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Notably he led the team that discovered and developed the first complement factor B inhibitor now in late clinical development across a range of indications. Before founding Kymera, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics. Nello has authored >60 papers and patents and has written reviews in the areas of medicinal chemistry, drug discovery and protein degradation. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

What is Nello Mainolfi's net worth?

The estimated net worth of Nello Mainolfi is at least $19.21 million as of August 4th, 2021. Dr. Mainolfi owns 457,868 shares of Kymera Therapeutics stock worth more than $19,212,141 as of November 17th. This net worth estimate does not reflect any other assets that Dr. Mainolfi may own. Additionally, Dr. Mainolfi receives a salary of $1,080,000.00 as CEO at Kymera Therapeutics. Learn More about Nello Mainolfi's net worth.

How old is Nello Mainolfi?

Dr. Mainolfi is currently 45 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. Learn More on Nello Mainolfi's age.

What is Nello Mainolfi's salary?

As the CEO of Kymera Therapeutics, Inc., Dr. Mainolfi earns $1,080,000.00 per year. Learn More on Nello Mainolfi's salary.

How do I contact Nello Mainolfi?

The corporate mailing address for Dr. Mainolfi and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Nello Mainolfi's contact information.

Has Nello Mainolfi been buying or selling shares of Kymera Therapeutics?

Nello Mainolfi has not been actively trading shares of Kymera Therapeutics during the past quarter. Most recently, Nello Mainolfi sold 8,612 shares of the business's stock in a transaction on Wednesday, January 12th. The shares were sold at an average price of $52.08, for a transaction totalling $448,512.96. Learn More on Nello Mainolfi's trading history.

Who are Kymera Therapeutics' active insiders?

Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.

Are insiders buying or selling shares of Kymera Therapeutics?

In the last twelve months, insiders at the sold shares 16 times. They sold a total of 1,008,191 shares worth more than $40,176,324.03. The most recent insider tranaction occured on September, 17th when Director Pamela Esposito sold 13,500 shares worth more than $651,780.00. Insiders at Kymera Therapeutics own 15.8% of the company. Learn More about insider trades at Kymera Therapeutics.

Information on this page was last updated on 9/17/2024.

Nello Mainolfi Insider Trading History at Kymera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2022Sell8,612$52.08$448,512.96View SEC Filing Icon  
1/10/2022Sell22,465$53.26$1,196,485.90View SEC Filing Icon  
10/11/2021Sell6,456$53.68$346,558.08View SEC Filing Icon  
10/8/2021Sell41,544$56.76$2,358,037.44View SEC Filing Icon  
8/4/2021Sell1,037$60.03$62,251.11457,868View SEC Filing Icon  
8/2/2021Sell23,456$60.30$1,414,396.80452,879View SEC Filing Icon  
7/30/2021Sell6,279$60.07$377,179.53View SEC Filing Icon  
7/28/2021Sell3,864$60.15$232,419.60461,214View SEC Filing Icon  
7/26/2021Sell9,015$60.15$542,252.25461,214View SEC Filing Icon  
7/8/2021Sell48,000$49.70$2,385,600.00500,199View SEC Filing Icon  
6/9/2021Sell5,752$50.02$287,715.04424,923View SEC Filing Icon  
6/7/2021Sell12,724$50.14$637,981.36424,923View SEC Filing Icon  
5/12/2021Sell8,245$50.05$412,662.25405,444View SEC Filing Icon  
4/26/2021Sell2,768$40.18$111,218.24408,158View SEC Filing Icon  
4/23/2021Sell680$40.01$27,206.80408,158View SEC Filing Icon  
4/19/2021Sell653$40.00$26,120.00396,139View SEC Filing Icon  
4/15/2021Sell4,940$40.29$199,032.60396,139View SEC Filing Icon  
4/12/2021Sell15,267$32.62$498,009.54386,138View SEC Filing Icon  
4/9/2021Sell22,794$33.68$767,701.92386,138View SEC Filing Icon  
See Full Table

Nello Mainolfi Buying and Selling Activity at Kymera Therapeutics

This chart shows Nello Mainolfi's buying and selling at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kymera Therapeutics Company Overview

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $41.96
Low: $41.50
High: $45.45

50 Day Range

MA: $47.17
Low: $41.96
High: $52.40

2 Week Range

Now: $41.96
Low: $16.94
High: $53.27

Volume

827,514 shs

Average Volume

385,346 shs

Market Capitalization

$2.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21
[Urgent] Starlink Set For The Largest IPO In History?
From Paradigm Press   |   Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
Click here now for the urgent details on this hidden play.